Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

High-throughput screening identifies compounds that enhance lentiviral transduction

Abstract

A difficulty in the field of gene therapy is the need to increase the susceptibility of hematopoietic stem cells (HSCs) to ex vivo genetic manipulation. To overcome this obstacle a high-throughput screen was performed to identify compounds that could enhance the transduction of target cells by lentiviral vectors. Of the 1280 compounds initially screened using the myeloid-erythroid-leukemic K562 cell line, 30 were identified as possible enhancers of viral transduction. Among the positive hits were known enhancers of transduction (camptothecin, etoposide and taxol), as well as the previously unidentified phorbol 12-myristate 13-acetate (PMA). The percentage of green fluorescent protein (GFP)-positive-expressing K562 cells was increased more than fourfold in the presence of PMA. In addition, the transduction of K562 cells with a lentiviral vector encoding fVIII was four times greater in the presence of PMA as determined by an increase in the levels of provirus in genetically modified cells. PMA did not enhance viral transduction of all cell types (for example, sca-1+ mouse hematopoietic cells) but did enhance viral transduction of human bone marrow-derived CD34+ cells. Notably, the percentage of GFP-positive CD34+ cells was increased from 7% in the absence of PMA to greater than 22% in the presence of 1 nM PMA. PMA did not affect colony formation of CD34+ cells or the expression of the hematopoietic markers CD34 and CD45. These data demonstrate that high-throughput screening can be used to identify compounds that increase the transduction efficiency of lentiviral vectors, identifying PMA as a potential enhancer of lentiviral HSC transduction.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10

Similar content being viewed by others

References

  1. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326: 818–823.

    Article  CAS  Google Scholar 

  2. Boztug K, Schnmidt M, Schwarzer A, Banerjee PP, Díez IA, Dewey RA et al. Stem-cell therapy for Wiskott-Aldrich syndrome. N Engl J Med 2010; 363: 1918–1927.

    Article  CAS  Google Scholar 

  3. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalasseaemia. Nature 2010; 467: 318–322.

    Article  CAS  Google Scholar 

  4. DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2010; 2: 36–43.

    Article  Google Scholar 

  5. Kumar M, Keller B, Makalou N, Sutton RE Systemic determination of the packaging limit of lentiviral vectors. Hum Gene Ther 2001; 12: 1893–1905.

    Article  CAS  Google Scholar 

  6. Yacoub N, Romanowska M, Haritonova N, Foerster J Optimized production and concentration of lentiviral vectors containing large inserts. J Gene Med 2007; 9: 579–584.

    Article  Google Scholar 

  7. Johnston J, Doering CB, Spencer HT Gene therapy strategies incorporating large transgenes. In: Chunsheng Kang(ed) Gene Therapy - Developments and Future Perspectives.. InTech: Croatia, 2011, pp 121–142.

    Google Scholar 

  8. Radcliffe P, Sion CJM, Wilkes EJ, Custard EJ, Beard GL, Kingsman SM et al. Analysis of factor VIII mediated suppression of lentiviral vector titres. Gene Therapy 2008; 15: 289–297.

    Article  CAS  Google Scholar 

  9. Lee HJ, Lee YS, Kim HS, Kim YK, Kim JH, Jeon SH et al. Retronectin enhances lentivirus-mediated gene delivery into hematopoietic progenitor cells. Biologicals 2009; 37: 203–209.

    Article  Google Scholar 

  10. Davis BM, Humeau L, Slepushkin V, Binder G, Korshalla L, Ni Y et al. ABC transporter inhibitors that are substrates enhance lentiviral vector transduction into primitive hematopoietic progenitor cells. Blood 2004; 104: 364–373.

    Article  CAS  Google Scholar 

  11. Leuci V, Mesiano G, Gammaitoni L, Cammarata C, Capellero S, Todorovic M et al. Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34+ cells and T lymphocytes: Implications for the use of low viral doses and large-size vectors. J Biotechnol 2011; 156: 218–226.

    Article  CAS  Google Scholar 

  12. Santoni de Sio FR, Cascio P, Zingale A, Gasparini M, Naldini L Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. Blood 2006; 107: 4257–4265.

    Article  CAS  Google Scholar 

  13. Millington M, Arndt A, Boyd M, Applegate T, Shen S Towards a clinically relevant transduction protocol for primary human CD34+ hematopoietic stem/progenitor cells. PLoS One 2009; 4: 1–10.

    Article  Google Scholar 

  14. Groeschel B, Bushman F Cell cycle arrest in G2/M promotes early steps of infection by human immunodeficiency virus. J Virol 2005; 79: 5695–5704.

    Article  Google Scholar 

  15. Pommier Y, Leo E, Zhang H, Marchand C DVA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010; 17: 421–433.

    Article  CAS  Google Scholar 

  16. Stahelin RV, Wang J, Blatner NR, Rafter JD, Murray D, Cho W The origin of C1A-C2 interdomain interactions in protein kinase Cα. J Biol Chem 2005; 280: 36452–36463.

    Article  CAS  Google Scholar 

  17. Steinberg SF Structural basis of protein kinase c isoform function. Phys Rev 2008; 88: 1341–1378.

    CAS  Google Scholar 

  18. Papayannopoulou T, Nakamoto B, Yokochi T, Chait A, Kannagi R Human erythroleukemia cell line (HEL) undergoes a drastic macrophage-like shift with TPA. Blood 1983; 62: 832–845.

    CAS  PubMed  Google Scholar 

  19. Doering CB, Gangadharan B, Dukart HZ, Spencer HT Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity. Mol Ther 2007; 15: 1093–1099.

    Article  CAS  Google Scholar 

  20. Wang CX, Sather BD, Wang X, Adair J, Khan I, Singh S Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells. Blood 2014; 124: 913–923.

    Article  CAS  Google Scholar 

  21. Kustikova OS, Schiedlmeier B, Brugman MH, Stahlhut M, Bartels S, Li Z et al. Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther 2009; 17: 1537–1547.

    Article  CAS  Google Scholar 

  22. Mitchison JM Growth during the cell cycle. Int Rev Cytol 2003; 226: 165–258.

    Article  CAS  Google Scholar 

  23. Ono Y, Fujii T, Igarashi K, Kuno T, Tanaka C, Kikkawa U et al. Phorbol ester binding to protein kinase C requires a cysteine-rich zing-finger-like sequence. Proc Natl Acad Sci USA 1989; 86: 4868–4871.

    Article  CAS  Google Scholar 

  24. Kazanietz MG, Bustelo XR, Barbacid M, Kolch W, Mischak H, Wong G et al. Zinc finger domains and phorbol ester pharmacophore. Analysis of binding to mutated form of protein kinase C zeta and the vav and c-raf proto-oncogene products. J Biol Chem 1994; 269: 11590–11594.

    CAS  PubMed  Google Scholar 

  25. Kazanietz MG, Barchi JJ Jr, Omichinski JG, Blumberg PM Low affinity binding of phorbol esters to PKC and its cysteine-rich region in the absence of phospholipids. J Biol Chem 1995; 270: 14679–14684.

    Article  CAS  Google Scholar 

  26. Quest AF, Bardes ES, Bell RM A phorbol ester binding domain of protein kinase C gamma. Deletion analysis of the Cys2 domain defines a minimal 43-amino acid peptide. J Biol Chem 1994; 269: 2961–2970.

    CAS  PubMed  Google Scholar 

  27. Ron D, Kazanietz MG New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J 1999; 13: 1658–1676.

    Article  CAS  Google Scholar 

  28. Kazanietz MG Eyes wide shut: protein kinase C isozymes are not the only receptors for the phorbol ester tumor promoters. Mol Carcinog 2000; 28: 5–11.

    Article  CAS  Google Scholar 

  29. Tonn T, Herder C, Becker S, Seifried E, Grez M Generation and characterization of human hematopoietic cell lines expressing factor VIII. J Hematother Stem Cell Res 2002; 11: 695–704.

    Article  CAS  Google Scholar 

  30. Warrilow D, Gardner J, Darnell GA, Suhrbier A, Harrich D HIV type 1 inhibiton by protein kinase C modulatory compounds. AIDS Res Hum Retroviruses. 2006; 22: 854–864.

    Article  CAS  Google Scholar 

  31. Alexaki A, Quiterio SJ, Liu Y, Irish B, Kilareski E, Nonnemacher MR, Wigdahl B PMA-induced differentiation of a bone marrow progenitor cell line activates HIV-1 LTR-driven transcription. DNA Cell Biol 2007; 26: 387–394.

    Article  CAS  Google Scholar 

  32. Strair RK, Schaar D, Goodell L, Aisner J, Chin K, Eid J et al. Administration of a phorbol ester to patients with hematological malignancies: preliminiary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate. Clin Cancer Res 2002; 8: 2512–2518.

    CAS  PubMed  Google Scholar 

  33. Johnston J, Denning G, Doering CB, Spencer HT Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A. Gene Therapy 2013; 20: 607–615.

    Article  CAS  Google Scholar 

  34. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr . Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119–121.

    Article  CAS  Google Scholar 

  35. Gangadharan B, Parker ET, Ide LM, Spencer HT, Doering CB . High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells. Blood 2006; 107: 3859–3864.

    Article  CAS  Google Scholar 

  36. Spencer HT, Denning G, Gautney RE, Dropulic B, Roy AJ, Baranyi L et al. Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII. Mol Ther 2011; 19: 302–309.

    Article  CAS  Google Scholar 

  37. Doering CB, Healey JF, Parker ET, Barrow RT, Lollar P High level expression of recombinant porcine coagulation factor VIII. J Biol Chem 2002; 277: 38345–38349.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Arthur Nienhuis (St Jude University, Memphis, TN, USA) for the SIV vector system. This work was supported by grants from the National Heart, Lung and Blood Institute of the National Institutes of Health.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H T Spencer.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Johnston, J., Denning, G., Moot, R. et al. High-throughput screening identifies compounds that enhance lentiviral transduction. Gene Ther 21, 1008–1020 (2014). https://doi.org/10.1038/gt.2014.80

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gt.2014.80

This article is cited by

Search

Quick links